about
Modification of a hydrophobic layer by a point mutation in syntaxin 1A regulates the rate of synaptic vesicle fusionPhase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors.Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells.Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma.Immune responses in adult female volunteers during the bed-rest model of spaceflight: antibodies and cytokines.Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination.Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype.Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy.Mesenchymal stem cells expressing GD2 and CD271 correlate with breast cancer-initiating cells in bone marrow.Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myelomaInflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer CellsPre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells.Associations of cytokines, sleep patterns, and neurocognitive function in youth with HIV infectionPrognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation.Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer.High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer.Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation.Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.A Phase 2 Study of Preoperative Capecitabine and Concomitant Radiation in Women With Advanced Breast Cancer.Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancerThrombocytosis as a prognostic factor in inflammatory breast cancerElevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer
P50
Q21563602-1EC65804-8EBB-4590-AA39-0D89862F2BDBQ33394175-8530A246-C802-4913-B9A6-A421618AF422Q34043793-3088D97F-E7CE-441E-9ED9-1640B455BAEEQ34458449-1F2405F3-F11E-4039-92CB-7EF69CEB06CCQ34949530-F16C549E-8B25-443D-9D79-890BD82EC482Q35000278-54D93986-A7F2-4E90-90BA-925E661F3EF1Q35048136-B0A485D4-D9B5-4F1A-87FC-A5AE24773294Q35204595-652940A6-CD58-4E9A-BC22-C58EB047BDA7Q35591523-1570547C-442C-4010-8B8D-1BFBBF703FFEQ35630256-0819E6D5-4CC6-4C36-B711-E4089E1D751EQ35710589-BBDE366A-D028-4912-8BD4-E6B478AFB903Q35985276-EBB64652-73CF-4FC1-8DD9-D4D31A97E495Q36040724-FB071611-3E1E-4F7D-B466-52AF71EC6DD4Q36316580-9E5812A7-7BD5-49DF-972F-E6A1FFFACBD0Q36406697-E51A7DFD-2BD9-4FC2-94EC-A20BEF625138Q37015722-77A882F1-697D-444F-A53A-1B6F7BB19BFAQ37451898-B3EF5BAB-A614-4B9E-BBD9-BAE107285789Q37626532-C3C5F8AA-3D94-47B1-B17E-9F13DEED647AQ43011834-54C1B98C-2A66-4FF6-93D9-5C207F63776EQ51800605-7B28205C-3C95-4AFF-9DC2-5094D172ED38Q59529651-BC017ACC-9AFE-41C2-BD53-6A81EDE90E91Q88830148-94425E1C-E131-4599-8022-E6BC1BA367DBQ91754319-8EB826C1-FA4E-4623-8A2A-3F340359D3B3
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-4192-9644
@en
name
Evan N Cohen
@ast
Evan N Cohen
@en
Evan N Cohen
@es
Evan N Cohen
@nl
type
label
Evan N Cohen
@ast
Evan N Cohen
@en
Evan N Cohen
@es
Evan N Cohen
@nl
prefLabel
Evan N Cohen
@ast
Evan N Cohen
@en
Evan N Cohen
@es
Evan N Cohen
@nl
P106
P1153
24402616000
P31
P496
0000-0003-4192-9644